Press Releases

All Releases
AngioDynamics Reports Fiscal 2014 Third Quarter Financial Results
Apr 09, 2014
Net sales increase 8% over prior year to $88.2 million GAAP income per share of $0.14 ; Non-GAAP adjusted net income, excluding amortization, of $0.16 per share Adjusted EBITDA of $14.6 million Company's revenue guidance to $351 million - $355 million for FY14; Adjusted EPS, excluding amortization,
AngioDynamics to Report Fiscal 2014 Third Quarter Financial Results
Mar 25, 2014
ALBANY, N.Y. , March 25, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 third quarter financial results
AngioDynamics Awarded $74.9 Million in Case Against biolitec AG
Mar 20, 2014
ALBANY, N.Y. , March 20, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec AG.
AngioDynamics Receives Expanded FDA Clearance for AngioVac
Mar 11, 2014
ALBANY, N.Y. , March 11, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded
AngioDynamics Receives FDA Clearance for DuraMax Dialysis Catheter With BioFlo Technology to Reduce Catheter-Related Thrombus
Mar 07, 2014
ALBANY, N.Y. , March 7, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration granted 510(k) clearance
AngioDynamics Updates U.S. Tip Location Strategy
Mar 06, 2014

Company Acquires Rights to Celerity System, Including Next-Generation Navigation Technology

AngioDynamics to Present at the Barclays Global Healthcare Conference
Mar 03, 2014
ALBANY, N.Y. , March 3, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
AngioDynamics Reports Fiscal 2014 Second Quarter Financial Results
Jan 09, 2014
Net sales of $88.6 million GAAP income per share at break-even; Non-GAAP adjusted net income, excluding amortization, of $0.14 per share Adjusted EBITDA of $12.7 million Operating cash flow of $8.2 million Company raises low end of revenue guidance to $349-$353 million for FY14; reiterates adjusted
AngioDynamics to Present at 32nd Annual J.P. Morgan Healthcare Conference
Dec 18, 2013
ALBANY, N.Y. , Dec. 18, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to present at the 32 nd Annual J.P.
AngioDynamics to Report Fiscal 2014 Second Quarter Financial Results
Dec 12, 2013
ALBANY, N.Y. , Dec. 12, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 second quarter financial results
AngioDynamics Appoints John Soto Chief Commercial Officer
Dec 11, 2013
ALBANY, N.Y. , Dec. 11, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of John Soto as Chief Commercial Officer, a
AngioDynamics Comments on New Reimbursement Rate for Hospital-Based Varicose Vein Ablations
Dec 10, 2013
ALBANY, N.Y. , Dec. 10, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced the Centers for Medicare and Medicaid Services (CMS) has created a new
AngioDynamics Announces Operational Excellence Program
Dec 05, 2013

Company Expects to Save $15 Million to $18 Million Over the Next Three Years

AngioDynamics to Present at 25th Annual Piper Jaffray Healthcare Conference
Nov 20, 2013
ALBANY, N.Y. , Nov. 20, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, is scheduled to participate in a Q&A session at the 25 th Annual Piper Jaffray
AngioDynamics to Present at Upcoming Investor Conferences
Nov 04, 2013
ALBANY, N.Y. , Nov. 4, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,
AngioDynamics Achieves CE Approval for AngioVac
Oct 29, 2013

CE Mark Covers Venous Drainage Cannula and Cardiopulmonary Bypass Circuit; Cannula Indicated for Removal of Fresh, Soft Thrombi or Emboli

AngioDynamics Reports Fiscal 2014 First Quarter Financial Results
Oct 10, 2013
Net sales of $83.6 million GAAP net loss of $0.01 per share; Non-GAAP adjusted net income of $0.04 per share; Non-GAAP adjusted net income excluding amortization of $0.12 per share Adjusted EBITDA of $11.3 million Operating cash flow of $7.3 million versus prior year $5.6 million cash use Company
AngioDynamics Signs Multi-Year, Sole-Source Agreement With Large Integrated Delivery Network Group
Oct 10, 2013
ALBANY, N.Y. , Oct. 10, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has signed a sole-source, three-year port product agreement
AngioDynamics Announces First Patient Enrolled in PICC Related Obstruction of Flow (PROOF) Study
Oct 03, 2013

Multi-Center Study Investigates Whether BioFlo PICCs Are Associated With Reduced Catheter-Related Thrombosis

AngioDynamics Announces Debt Refinancing
Sep 24, 2013
ALBANY, N.Y. , Sept. 24, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it amended its existing credit facilities and successfully
Displaying 101 - 120 of 615

Copyright Nasdaq. Minimum 15 minutes delayed.